Tools
Francis, A, Fallowfield, L and Rea, D (2015) The LORIS trial: addressing overtreatment of ductal carcinoma in situ. Clinical Oncology, 27 (1). pp. 6-8. ISSN 0936-6555
Full text not available from this repository.
Official URL: http://dx.doi.org/10.1016/j.clon.2014.09.015
Abstract
An unforeseen consequence of the introduction of mammographic breast screening has been the marked increase in the number of women diagnosed with ductal carcinoma in situ (DCIS) [1,2]. In 2009–2010, 2830 women were diagnosed with in situ carcinoma through the National Health Service Breast Screening Programme (NHSBSP) [3]. Screen-detected DCIS now accounts for 20% of ‘cancers’ identified through breast screening. However, the intent of breast screening programmes was to detect early invasive cancer, not to identify DCIS.
Item Type: | Article |
---|---|
Schools and Departments: | Brighton and Sussex Medical School > Sussex Health Outcomes Research & Education in Cancer (SHORE-C) |
Subjects: | R Medicine > RC Internal medicine R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology Including cancer and carcinogens R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology Including cancer and carcinogens > RC0280 By region, system, or organ of the body, or type of tumor, A-Z > RC0280.B8 Breast. Mammary glands |
Depositing User: | Kathryn Monson |
Date Deposited: | 15 Dec 2014 15:03 |
Last Modified: | 01 Jun 2015 15:01 |
URI: | http://sro.sussex.ac.uk/id/eprint/51696 |